Survey on Minimal Residual Disease (MRD) Measurement in Multiple Myeloma
Not Applicable
- Conditions
- Multiple Myeloma
- Registration Number
- JPRN-UMIN000052475
- Lead Sponsor
- Sanofi K.K.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 158
Inclusion Criteria
Not provided
Exclusion Criteria
Not applicable
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To analyze the actual status of MRD measurement and its issues in the treatment of multiple myeloma and clarify unmet medical needs 1_Whether or not minimal residual disease (MRD) is measured 2_Whether or not imaging tests (PET/CT, MRI) are performed 3_Reasons for not measuring MRD 4_MRD measurement method 5_Criteria (detection sensitivity) 6_Purpose of measuring 7_Frequency of measurement
- Secondary Outcome Measures
Name Time Method I.To clarify the prospects for the MRD measurement method as a prognostic factor in the future II.To provide a basis for future evidence generation activities 1_Purpose of MRD measurement 2_What is needed to promote MRD measurement 3_Challenges of imaging tests